ArticleTranslational cancer research2026
LncRNA SOX21-AS1 is associated with poor prognosis and immunomodulation in glioblastoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Glioblastoma multiforme (GBM) is characterized by its aggressive nature and is the most malignant form of glioma, associated with a poor clinical prognosis. This study aimed to evaluate and predict the survival outcomes of GBM patients by developing a prognostic long non-coding RNA (lncRNA) signaling model for GBM. Methods: We utilized R software to analyze The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets, identifying differentially expressed genes (DEGs) using univariate Cox regression. A least absolute shrinkage and selection operator (LASSO) regression model was developed, and its predictive performance was assessed via receiver operating characteristic (ROC) curves and Kaplan-Meier survival analysis. Risk groups were validated through enrichment analysis, immune profiling, and drug sensitivity evaluation. Results: We constructed a risk prediction model incorporating 19 lncRNAs to categorize patients into high- and low-risk groups, with significant survival differences. The model exhibited high predictive accuracy [area under the curve (AUC) =0.95]. Immune infiltration analysis revealed elevated naïve B cells, M2 macrophages, and γδ T cells in high-risk patients, alongside upregulated programmed cell death 1 (PDCD1) and T Cell Immunoglobulin and ITIM Domain (TIGIT) but downregulated CD274 [programmed death-ligand 1 (PD-L1)]. Five immune-related hub genes ( Conclusions: Our findings suggest that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.